JP6100755B2 - (2−ヘテロアリールアミノ)コハク酸誘導体 - Google Patents
(2−ヘテロアリールアミノ)コハク酸誘導体 Download PDFInfo
- Publication number
- JP6100755B2 JP6100755B2 JP2014508120A JP2014508120A JP6100755B2 JP 6100755 B2 JP6100755 B2 JP 6100755B2 JP 2014508120 A JP2014508120 A JP 2014508120A JP 2014508120 A JP2014508120 A JP 2014508120A JP 6100755 B2 JP6100755 B2 JP 6100755B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- amino
- oxobutanoic acid
- compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000003443 succinic acid derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 211
- 208000007502 anemia Diseases 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 58
- 125000001424 substituent group Chemical group 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 33
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 30
- 102000003951 Erythropoietin Human genes 0.000 claims description 27
- 108090000394 Erythropoietin Proteins 0.000 claims description 27
- 229940105423 erythropoietin Drugs 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- OFFHPZOSXYMQKV-UHFFFAOYSA-N 4-[[5-[[4-(2-cyanophenyl)phenyl]methoxymethyl]pyridin-2-yl]amino]-4-oxobutanoic acid Chemical compound C1=NC(NC(=O)CCC(=O)O)=CC=C1COCC1=CC=C(C=2C(=CC=CC=2)C#N)C=C1 OFFHPZOSXYMQKV-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- BNQJVBJVMKWINO-UHFFFAOYSA-N 4-[[5-[(3-cyclopentylphenyl)methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=CC(C2CCCC2)=C1 BNQJVBJVMKWINO-UHFFFAOYSA-N 0.000 claims description 5
- PGOJDNCTSPJTKM-UHFFFAOYSA-N 4-[[5-[(4-fluoro-3-phenylphenyl)methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=C(F)C(C=2C=CC=CC=2)=C1 PGOJDNCTSPJTKM-UHFFFAOYSA-N 0.000 claims description 5
- MSFLVFPYMWNVJE-UHFFFAOYSA-N 4-[[5-[[3-(2-cyanophenyl)phenyl]methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=CC(C=2C(=CC=CC=2)C#N)=C1 MSFLVFPYMWNVJE-UHFFFAOYSA-N 0.000 claims description 5
- AICSZATVFXNQPP-UHFFFAOYSA-N 4-oxo-4-[[4-oxo-5-[(3-phenylphenyl)methylcarbamoyl]-1h-pyridin-2-yl]amino]butanoic acid Chemical compound N1C(NC(=O)CCC(=O)O)=CC(=O)C(C(=O)NCC=2C=C(C=CC=2)C=2C=CC=CC=2)=C1 AICSZATVFXNQPP-UHFFFAOYSA-N 0.000 claims description 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 4
- HKHBOEFLIDUMOH-UHFFFAOYSA-N 4-[[5-(naphthalen-1-ylmethylcarbamoyl)-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=CC2=CC=CC=C12 HKHBOEFLIDUMOH-UHFFFAOYSA-N 0.000 claims description 4
- SCLQGYRRNOKULA-UHFFFAOYSA-N 4-[[5-(naphthalen-2-ylmethylcarbamoyl)-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=C(C=CC=C2)C2=C1 SCLQGYRRNOKULA-UHFFFAOYSA-N 0.000 claims description 4
- ZJGADHMNPQYOMK-UHFFFAOYSA-N 4-[[5-[(2,4-dichlorophenyl)methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=C(Cl)C=C1Cl ZJGADHMNPQYOMK-UHFFFAOYSA-N 0.000 claims description 4
- YUENKXHEBQNIPY-UHFFFAOYSA-N 4-[[5-[(2,4-difluorophenyl)methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=C(F)C=C1F YUENKXHEBQNIPY-UHFFFAOYSA-N 0.000 claims description 4
- DLZCDOCUBRXELH-UHFFFAOYSA-N 4-[[5-[(2-chloro-4-fluorophenyl)methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=C(F)C=C1Cl DLZCDOCUBRXELH-UHFFFAOYSA-N 0.000 claims description 4
- VJYUAZTXMWZEFG-UHFFFAOYSA-N 4-[[5-[(3,4-difluorophenyl)methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=C(F)C(F)=C1 VJYUAZTXMWZEFG-UHFFFAOYSA-N 0.000 claims description 4
- AGRLNWKIYXBVFT-UHFFFAOYSA-N 4-[[5-[(3-fluorophenyl)methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=CC(F)=C1 AGRLNWKIYXBVFT-UHFFFAOYSA-N 0.000 claims description 4
- GZGGDIGCDHQULH-UHFFFAOYSA-N 4-[[5-[(3-methylphenyl)methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound CC1=CC=CC(CNC(=O)C=2C(NC(NC(=O)CCC(O)=O)=NC=2)=O)=C1 GZGGDIGCDHQULH-UHFFFAOYSA-N 0.000 claims description 4
- SAIHLTZUGCTCFF-UHFFFAOYSA-N 4-[[5-[(4-methylphenyl)methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound C1=CC(C)=CC=C1CNC(=O)C1=CN=C(NC(=O)CCC(O)=O)NC1=O SAIHLTZUGCTCFF-UHFFFAOYSA-N 0.000 claims description 4
- VITAVZVAJONNCR-UHFFFAOYSA-N 4-[[5-[[4-(2-cyanophenyl)phenyl]methylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=C(C=2C(=CC=CC=2)C#N)C=C1 VITAVZVAJONNCR-UHFFFAOYSA-N 0.000 claims description 4
- RRJBOWPBQSTVLT-UHFFFAOYSA-N 4-oxo-4-[[5-[(4-phenylphenyl)methoxymethyl]pyridin-2-yl]amino]butanoic acid Chemical compound C1=NC(NC(=O)CCC(=O)O)=CC=C1COCC1=CC=C(C=2C=CC=CC=2)C=C1 RRJBOWPBQSTVLT-UHFFFAOYSA-N 0.000 claims description 4
- VCOPQSOIAYXCGU-UHFFFAOYSA-N 4-oxo-4-[[6-oxo-5-[(3-phenylphenyl)methylcarbamoyl]-1h-pyrimidin-2-yl]amino]butanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=CC(C=2C=CC=CC=2)=C1 VCOPQSOIAYXCGU-UHFFFAOYSA-N 0.000 claims description 4
- FTHPCAJRGQRDHC-UHFFFAOYSA-N 4-oxo-4-[[6-oxo-5-[[3-(trifluoromethyl)phenyl]methylcarbamoyl]-1h-pyrimidin-2-yl]amino]butanoic acid Chemical compound O=C1NC(NC(=O)CCC(=O)O)=NC=C1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 FTHPCAJRGQRDHC-UHFFFAOYSA-N 0.000 claims description 4
- UGMWGHMDBHGGOW-UHFFFAOYSA-N 4-[[5-[2-[6-(4-methoxyphenyl)pyridin-3-yl]propan-2-ylcarbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(C)(C)NC(=O)C=2C(NC(NC(=O)CCC(O)=O)=NC=2)=O)C=N1 UGMWGHMDBHGGOW-UHFFFAOYSA-N 0.000 claims description 3
- QCQGEDBNBPQELS-UHFFFAOYSA-N 4-[[5-[[(6-methoxypyridin-3-yl)-(oxan-4-yl)methyl]carbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid Chemical compound C1=NC(OC)=CC=C1C(C1CCOCC1)NC(=O)C1=CN=C(NC(=O)CCC(O)=O)NC1=O QCQGEDBNBPQELS-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- 238000006243 chemical reaction Methods 0.000 description 62
- -1 succinic acid compound Chemical class 0.000 description 55
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- 239000002904 solvent Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000002994 raw material Substances 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 19
- 239000002585 base Substances 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 238000010898 silica gel chromatography Methods 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 239000000725 suspension Substances 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 12
- 238000007796 conventional method Methods 0.000 description 12
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 12
- 239000012046 mixed solvent Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- WKHABRRJMGVELW-UHFFFAOYSA-N (3-phenylphenyl)methanamine Chemical compound NCC1=CC=CC(C=2C=CC=CC=2)=C1 WKHABRRJMGVELW-UHFFFAOYSA-N 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000020832 chronic kidney disease Diseases 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 230000035484 reaction time Effects 0.000 description 9
- 238000001226 reprecipitation Methods 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 8
- 208000017667 Chronic Disease Diseases 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000012156 elution solvent Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 8
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- SJUKJZSTBBSGHF-UHFFFAOYSA-N (2,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1Cl SJUKJZSTBBSGHF-UHFFFAOYSA-N 0.000 description 7
- 206010007559 Cardiac failure congestive Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 206010019280 Heart failures Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 150000007530 organic bases Chemical class 0.000 description 7
- 230000002028 premature Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 5
- 208000020459 Anaemia of malignant disease Diseases 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 229940117389 dichlorobenzene Drugs 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 4
- PCOCFIOYWNCGBM-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)CCC(O)=O PCOCFIOYWNCGBM-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 102000044890 human EPO Human genes 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- FDDXPIIDDITNEP-UHFFFAOYSA-N (4-fluoro-3-phenylphenyl)methanamine Chemical compound NCC1=CC=C(F)C(C=2C=CC=CC=2)=C1 FDDXPIIDDITNEP-UHFFFAOYSA-N 0.000 description 2
- HZQLUIZFUXNFHK-UHFFFAOYSA-N 1-(bromomethyl)-4-phenylbenzene Chemical compound C1=CC(CBr)=CC=C1C1=CC=CC=C1 HZQLUIZFUXNFHK-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 2
- IRIYFXOLIHAQMJ-UHFFFAOYSA-N C1(=CC=CC=C1)C1=CC=C(C=C1)COCC=1C=CC(=NC1)N Chemical compound C1(=CC=CC=C1)C1=CC=C(C=C1)COCC=1C=CC(=NC1)N IRIYFXOLIHAQMJ-UHFFFAOYSA-N 0.000 description 2
- CAJDNKYZDWPBAA-UHFFFAOYSA-N CC(C)(C)OC(=O)N(Cc1cccc(c1)C1CCCC1)C(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)N(Cc1cccc(c1)C1CCCC1)C(=O)OC(C)(C)C CAJDNKYZDWPBAA-UHFFFAOYSA-N 0.000 description 2
- MIHUUGMLTGMRII-UHFFFAOYSA-N COC1=C(C=CC(=C1)OC)CNC1=CC(=C(C=N1)C(=O)O)OC Chemical compound COC1=C(C=CC(=C1)OC)CNC1=CC(=C(C=N1)C(=O)O)OC MIHUUGMLTGMRII-UHFFFAOYSA-N 0.000 description 2
- MNTXXMCMVQTKMP-UHFFFAOYSA-N COC1=C(C=CC(=C1)OC)CNC1=CC(=C(C=N1)C(=O)OC)OC Chemical compound COC1=C(C=CC(=C1)OC)CNC1=CC(=C(C=N1)C(=O)OC)OC MNTXXMCMVQTKMP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 2
- DOBPUHQTQSUOGO-UHFFFAOYSA-N Cl.NCc1cccc(c1)-c1ccccc1C#N Chemical compound Cl.NCc1cccc(c1)-c1ccccc1C#N DOBPUHQTQSUOGO-UHFFFAOYSA-N 0.000 description 2
- KIEYONGQXFAGKH-UHFFFAOYSA-N Cl.NCc1cccc(c1)C1CCCC1 Chemical compound Cl.NCc1cccc(c1)C1CCCC1 KIEYONGQXFAGKH-UHFFFAOYSA-N 0.000 description 2
- OMSYVYCNHYYKFM-UHFFFAOYSA-N ClC1=NC=C(C=C1)COCC1=CC=C(C=C1)C1=CC=CC=C1 Chemical compound ClC1=NC=C(C=C1)COCC1=CC=C(C=C1)C1=CC=CC=C1 OMSYVYCNHYYKFM-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- ONNDQQQMWLJWIL-UHFFFAOYSA-N Nc1ncc(C(=O)NCc2ccc(Cl)cc2Cl)c(O)n1 Chemical compound Nc1ncc(C(=O)NCc2ccc(Cl)cc2Cl)c(O)n1 ONNDQQQMWLJWIL-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 2
- 125000004145 cyclopenten-1-yl group Chemical group [H]C1=C(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 2
- 229940044173 iodine-125 Drugs 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- QDZZDVQGBKTLHV-UHFFFAOYSA-N (2,4-difluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1F QDZZDVQGBKTLHV-UHFFFAOYSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- CBKWAXKMZUULLO-UHFFFAOYSA-N (2-chloro-4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1Cl CBKWAXKMZUULLO-UHFFFAOYSA-N 0.000 description 1
- PHLZUDXEBCQHKM-UHFFFAOYSA-N (3,4-difluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C(F)=C1 PHLZUDXEBCQHKM-UHFFFAOYSA-N 0.000 description 1
- QVSVMNXRLWSNGS-UHFFFAOYSA-N (3-fluorophenyl)methanamine Chemical compound NCC1=CC=CC(F)=C1 QVSVMNXRLWSNGS-UHFFFAOYSA-N 0.000 description 1
- RGXUCUWVGKLACF-UHFFFAOYSA-N (3-methylphenyl)methanamine Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 description 1
- HMTSWYPNXFHGEP-UHFFFAOYSA-N (4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1 HMTSWYPNXFHGEP-UHFFFAOYSA-N 0.000 description 1
- GOXYBEXWMJZLJB-UHFFFAOYSA-N (6-chloropyridin-3-yl)methanol Chemical compound OCC1=CC=C(Cl)N=C1 GOXYBEXWMJZLJB-UHFFFAOYSA-N 0.000 description 1
- DPQNDGMUYJAZDT-UHFFFAOYSA-N (6-methoxypyridin-3-yl)-(oxan-4-yl)methanamine;hydrochloride Chemical compound Cl.C1=NC(OC)=CC=C1C(N)C1CCOCC1 DPQNDGMUYJAZDT-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 1,2-dimethoxyethane;hydrate Chemical compound O.COCCOC ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- JFTZVYKESKQING-UHFFFAOYSA-N 2-(cyclopenten-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCCC1 JFTZVYKESKQING-UHFFFAOYSA-N 0.000 description 1
- LRGAANMQNVMQFA-UHFFFAOYSA-N 2-[4-(aminomethyl)phenyl]benzonitrile Chemical compound C1=CC(CN)=CC=C1C1=CC=CC=C1C#N LRGAANMQNVMQFA-UHFFFAOYSA-N 0.000 description 1
- LFFIEVAMVPCZNA-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]benzonitrile Chemical compound C1=CC(CBr)=CC=C1C1=CC=CC=C1C#N LFFIEVAMVPCZNA-UHFFFAOYSA-N 0.000 description 1
- GBADBFAXAWZGHM-UHFFFAOYSA-N 2-amino-6-oxo-1h-pyrimidine-5-carboxylic acid Chemical compound NC1=NC=C(C(O)=O)C(O)=N1 GBADBFAXAWZGHM-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- GGVMSLOIZJIWSD-UHFFFAOYSA-N 2-methoxy-4-oxobutanoic acid Chemical compound COC(C(O)=O)CC=O GGVMSLOIZJIWSD-UHFFFAOYSA-N 0.000 description 1
- 125000005975 2-phenylethyloxy group Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VAHOGDDGOLUVFF-UHFFFAOYSA-N 4-[[5-[[(6-methoxypyridin-3-yl)-(oxan-4-yl)methyl]carbamoyl]-6-oxo-1h-pyrimidin-2-yl]amino]-4-oxobutanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=NC(OC)=CC=C1C(C1CCOCC1)NC(=O)C1=CN=C(NC(=O)CCC(O)=O)NC1=O VAHOGDDGOLUVFF-UHFFFAOYSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- HMBHBNGUHJVICW-UHFFFAOYSA-N 4-fluoro-3-phenylbenzonitrile Chemical group FC1=CC=C(C#N)C=C1C1=CC=CC=C1 HMBHBNGUHJVICW-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- BEUMBMWUTPTRGO-UHFFFAOYSA-N 5-hydroxypyrimidine-4-carboxamide Chemical class NC(=O)C1=NC=NC=C1O BEUMBMWUTPTRGO-UHFFFAOYSA-N 0.000 description 1
- ZOSXLRUOBVSFQV-UHFFFAOYSA-N 6-oxo-1h-pyrimidine-5-carboxamide Chemical class NC(=O)C1=CN=CN=C1O ZOSXLRUOBVSFQV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- DJKABLGXQIURDB-UHFFFAOYSA-N COC1=C(C=CC(=C1)OC)CN(C(CCC(=O)OC(C)(C)C)=O)C1=NC=C(C(=C1)OC)C(NCC1=CC(=CC=C1)C1=CC=CC=C1)=O Chemical compound COC1=C(C=CC(=C1)OC)CN(C(CCC(=O)OC(C)(C)C)=O)C1=NC=C(C(=C1)OC)C(NCC1=CC(=CC=C1)C1=CC=CC=C1)=O DJKABLGXQIURDB-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RDMLOKMSQIXHKC-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)CNC(=O)C=1C(=NC(=NC1)NC(CCC(=O)OC(C)(C)C)=O)O Chemical compound ClC1=C(C=CC(=C1)Cl)CNC(=O)C=1C(=NC(=NC1)NC(CCC(=O)OC(C)(C)C)=O)O RDMLOKMSQIXHKC-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- MPBNYXZNCYCCEJ-UHFFFAOYSA-N FC(C(=O)O)(F)F.OC1=NC(=NC=C1C(NC(C)(C)C=1C=NC(=CC1)C1=CC=C(C=C1)OC)=O)NC(CCC(=O)O)=O Chemical compound FC(C(=O)O)(F)F.OC1=NC(=NC=C1C(NC(C)(C)C=1C=NC(=CC1)C1=CC=C(C=C1)OC)=O)NC(CCC(=O)O)=O MPBNYXZNCYCCEJ-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- AJPVWYQTAQQIKA-UHFFFAOYSA-N O=C(CCC(=O)OC)NC1=NC=C(C=C1)COCC1=CC=C(C=C1)C1=CC=CC=C1 Chemical compound O=C(CCC(=O)OC)NC1=NC=C(C=C1)COCC1=CC=C(C=C1)C1=CC=CC=C1 AJPVWYQTAQQIKA-UHFFFAOYSA-N 0.000 description 1
- YADVHSCWPDEKSA-UHFFFAOYSA-N OC1=NC(=NC=C1C(NCC1=CC(=CC=C1)C1=CC=CC=C1)=O)NC(CCC(=O)OC(C)(C)C)=O Chemical compound OC1=NC(=NC=C1C(NCC1=CC(=CC=C1)C1=CC=CC=C1)=O)NC(CCC(=O)OC(C)(C)C)=O YADVHSCWPDEKSA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- NPTBTFRGCBFYPZ-UHFFFAOYSA-N [3-(aminomethyl)phenyl]boronic acid;hydrochloride Chemical compound [Cl-].[NH3+]CC1=CC=CC(B(O)O)=C1 NPTBTFRGCBFYPZ-UHFFFAOYSA-N 0.000 description 1
- YKNZTUQUXUXTLE-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(C(F)(F)F)=C1 YKNZTUQUXUXTLE-UHFFFAOYSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- PQLAYKMGZDUDLQ-UHFFFAOYSA-K aluminium bromide Chemical compound Br[Al](Br)Br PQLAYKMGZDUDLQ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- VEQSINZLZMKYNU-UHFFFAOYSA-N benzenesulfonic acid;2-[6-(4-methoxyphenyl)pyridin-3-yl]propan-2-amine Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OC)=CC=C1C1=CC=C(C(C)(C)N)C=N1 VEQSINZLZMKYNU-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- HDULBKVLSJEMGN-UHFFFAOYSA-N dicyclohexylphosphane Chemical compound C1CCCCC1PC1CCCCC1 HDULBKVLSJEMGN-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- CRHWEIDCXNDTMO-UHFFFAOYSA-N ditert-butylphosphane Chemical compound CC(C)(C)PC(C)(C)C CRHWEIDCXNDTMO-UHFFFAOYSA-N 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- CRTSQMSTPZTUDW-UHFFFAOYSA-N methyl 6-chloro-4-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C=C1OC CRTSQMSTPZTUDW-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 1
- XBCAHQUVHHVHHL-UHFFFAOYSA-N naphthalen-2-ylmethanamine Chemical compound C1=CC=CC2=CC(CN)=CC=C21 XBCAHQUVHHVHHL-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001828 phenalenyl group Chemical group C1(C=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MHXRBUKPQNITJB-UHFFFAOYSA-N tert-butyl n-[(3-bromophenyl)methyl]-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(Br)=C1 MHXRBUKPQNITJB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
[1]一般式(1)
R1は、独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよい芳香族炭化水素環基、又は独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよい芳香族複素環基を示し、
置換基群αは、ハロゲン原子、C1〜C4アルキル基、ハロゲノC1〜C4アルキル基、C1〜C4アルコキシ基、C3〜C6シクロアルキル基、又はR4が置換していてもよい芳香族炭化水素環基からなる群を示し、
R2は、水素原子、C1〜C4アルキル基、又は4〜7員ヘテロシクロアルキル基を示し、
R3は、水素原子、又はC1〜C4アルキル基を示し、
R4は、シアノ基、ハロゲン原子、又はC1〜C4アルコキシ基を示し、
Aは、水素原子、又は水酸基を示し、
Lは、式−NHCO−で表される基、又は式−OCH2−で表される基を示し、
Xは、窒素原子、又は式=CH−で表わされる基を示す。]
で表される化合物、又はその薬理上許容される塩、
[2]R1が、独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよいフェニル基、ナフチル基、ピリジル基、ピリミジニル基、ピラジニル基、又はピリダジニル基である[1]に記載の化合物、又はその薬理上許容される塩、
[3]R1が、独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよいフェニル基、ナフチル基、又はピリジル基である[1]に記載の化合物、又はその薬理上許容される塩、
[4]R1が、独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよいフェニル基、又はピリジル基である[1]に記載の化合物、又はその薬理上許容される塩。
[5]置換基群αが、フッ素原子、塩素原子、メチル基、トリフルオロメチル基、メトキシ基、シクロペンチル基、又はR4が置換していてもよいフェニル基からなる群であり、
R4が、シアノ基、又はメトキシ基である[1]乃至[4]のいずれか1項に記載の化合物、又はその薬理上許容される塩、
[6]置換基群αが、フッ素原子、塩素原子、トリフルオロメチル基、メトキシ基、又はR4が置換していてもよいフェニル基からなる群であり、
R4がメトキシ基である[1]乃至[4]のいずれか1項に記載の化合物、又はその薬理上許容される塩、
[7]R2が、水素原子、メチル基、又はテトラヒドロピラニル基である[1]乃至[6]のいずれか1項に記載の化合物、又はその薬理上許容される塩、
[8]R3が、水素原子、又はメチル基である[1]乃至[7]のいずれか1項に記載の化合物、又はその薬理上許容される塩、
[9]Aが、水酸基である[1]乃至[8]のいずれか1項に記載の化合物、又はその薬理上許容される塩、
[10]Lが、式−NHCO−で表される基である[1]乃至[9]のいずれか1項に記載の化合物、又はその薬理上許容される塩、
[11]Xが、窒素原子である[1]乃至[10]いずれか1項に記載の化合物、又はその薬理上許容される塩。
[12]上記[1]において、下記から選ばれる化合物、又はその薬理上許容される塩:
4−({5−[(2,4−ジクロロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({5−[(2,4−ジフルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({5−[(2−クロロ−4−フルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(p−トリルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−({5−[(4−フルオロ−3−フェニルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]ピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−[(5−{[4−(2−シアノフェニル)フェニル]メチルカルバモイル}−4−ヒドロキシピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−[(5−{[3−(2−シアノフェニル)フェニル]メチルカルバモイル}−4−ヒドロキシピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−[(4−ヒドロキシ−5−{[(6−メトキシピリジン−3−イル)(テトラヒドロ−2H−ピラン−4−イル)メチル]カルバモイル}ピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−({1−[6−(4−メトキシフェニル)ピリジン−3−イル]−1−メチルエチル}カルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−[(4−ヒドロキシ−5−{[3−(トリフルオロメチル)フェニル]メチルカルバモイル}ピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−({5−[(3−フルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({5−[(3,4−ジフルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(m−トリルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(1−ナフチルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(2−ナフチルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−({5−[(3−シクロペンチルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]−2−ピリジル}アミノ)−4−オキソブタン酸、
4−オキソ−4−({5−[(4−フェニルフェニル)メトキシメチル]−2−ピリジル}アミノ)ブタン酸、
4−[(5−{[4−(2−シアノフェニル)フェニル]メトキシメチル}−2−ピリジル)アミノ]−4−オキソブタン酸。
[13]上記[1]乃至[12]のいずれか1項に記載の化合物、又はその薬理上許容される塩を有効成分として含有する医薬組成物、
[14]貧血の予防及び/又は治療のための、上記[13]に記載の医薬組成物、
[15]貧血が、腎性貧血、未熟児貧血、慢性疾患に伴う貧血、癌化学療法に伴う貧血、癌性貧血、炎症関連性の貧血、又はうっ血性心不全に伴う貧血である、上記[14]に記載の医薬組成物、
[16]貧血が、慢性腎臓疾患に伴う貧血である、上記[14]に記載の医薬組成物、
[17]エリスロポエチンを産生するための、上記[13]に記載の医薬組成物、
[18]医薬を製造するための、上記[1]乃至[12]のいずれか1項に記載の化合物、又はその薬理上許容される塩の使用、
[19]医薬が、貧血の予防及び/又は治療のための医薬である、上記[18]に記載の使用、
[20]貧血が、腎性貧血、未熟児貧血、慢性疾患に伴う貧血、癌化学療法に伴う貧血、癌性貧血、炎症関連性の貧血、又はうっ血性心不全に伴う貧血である、上記[19]に記載の使用、
[21]貧血が、慢性腎臓疾患に伴う貧血である、上記[19]に記載の使用、
[22]上記[1]乃至[12]のいずれか1項に記載の化合物、又はその薬理上許容される塩の薬理的有効量を哺乳動物又は鳥類に投与することからなる、エリスロポエチンを産生する方法、
[23]上記[1]乃至[12]のいずれか1項に記載の化合物、又はその薬理上許容される塩の薬理的有効量を哺乳動物に投与することからなる、疾患の治療又は予防のための方法、
[24]疾患が、貧血である、上記[23]に記載の方法、
[25]疾患が、腎性貧血、未熟児貧血、慢性疾患に伴う貧血、癌化学療法に伴う貧血、癌性貧血、炎症関連性の貧血、又はうっ血性心不全に伴う貧血である、上記[23]に記載の方法、
[26]疾患が、慢性腎臓疾患に伴う貧血である、上記[23]に記載の方法、
[27]哺乳動物が、ヒトである、上記[23]乃至[26]のいずれか1項に記載の方法、
[28]疾患の治療又は予防のための方法における使用のための、上記[1]乃至[12]のいずれか1項に記載の化合物、又はその薬理上許容される塩、
[29]疾患が、貧血である、上記[28]に記載の化合物、又はその薬理上許容される塩、
[30]疾患が、腎性貧血、未熟児貧血、慢性疾患に伴う貧血、癌化学療法に伴う貧血、癌性貧血、炎症関連性の貧血、又はうっ血性心不全に伴う貧血である、上記[28]に記載の化合物、又はその薬理上許容される塩、又は、
[31]疾患が、慢性腎臓疾患に伴う貧血である、上記[28]に記載の化合物、又はその薬理上許容される塩
である。
上記一般式(1)で表される本発明の化合物は、(2−ヘテロアリールアミノ)コハク酸骨格を有し、当該ヘテロアリール環5位の置換基は、1又は2個の環状基を有し、当該環状基は特定の置換基を有する。本発明の化合物、又はその薬理上許容される塩は、優れたEPO産生増強活性を有する。
4−({5−[(2,4−ジクロロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({5−[(2,4−ジフルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({5−[(2−クロロ−4−フルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(p−トリルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−({5−[(4−フルオロ−3−フェニルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]ピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−[(5−{[4−(2−シアノフェニル)フェニル]メチルカルバモイル}−4−ヒドロキシピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−[(5−{[3−(2−シアノフェニル)フェニル]メチルカルバモイル}−4−ヒドロキシピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−[(4−ヒドロキシ−5−{[(6−メトキシピリジン−3−イル)(テトラヒドロ−2H−ピラン−4−イル)メチル]カルバモイル}ピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−({1−[6−(4−メトキシフェニル)ピリジン−3−イル]−1−メチルエチル}カルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−[(4−ヒドロキシ−5−{[3−(トリフルオロメチル)フェニル]メチルカルバモイル}ピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−({5−[(3−フルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({5−[(3,4−ジフルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(m−トリルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(1−ナフチルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(2−ナフチルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−({5−[(3−シクロペンチルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]−2−ピリジル}アミノ)−4−オキソブタン酸、
4−オキソ−4−({5−[(4−フェニルフェニル)メトキシメチル]−2−ピリジル}アミノ)ブタン酸、
4−[(5−{[4−(2−シアノフェニル)フェニル]メトキシメチル}−2−ピリジル)アミノ]−4−オキソブタン酸。
(製造法1)
製造法1は、本発明の化合物(1)におけるLが式−NHCO−で表される基であり、かつ、Xが窒素原子である化合物(1a)を製造する方法である。
(工程1−1)
本工程は、反応に不活性な溶媒中、縮合剤及び塩基の存在下、化合物(2)及び化合物(3)から化合物(4)を製造する工程である。
(工程1−2)
本工程は、反応に不活性な溶媒中、縮合剤及び塩基の存在下、化合物(4)及び化合物(5)から化合物(6)を製造する工程である。
(工程1−3)
本工程は、反応に不活性な溶媒中、酸の存在下、化合物(6)から本発明の化合物(1a)を製造する工程である。
(製造法2)
製造法2は、本発明の化合物(1)におけるAが水酸基であり、Lが式−NHCO−で表される基であり、かつ、Xが式=CH−で表される基である化合物(1b)を製造する方法である。
(工程2−1)
本工程は、反応に不活性な溶媒中、塩基の存在下、化合物(7)及び化合物(8)から化合物(9)を製造する工程である。
(工程2−2)
本工程は、反応に不活性な溶媒中、塩基の存在下、化合物(9)から化合物(10)を製造する工程である。
(工程2−3)
本工程は、工程1−1と同様にして、化合物(3)及び化合物(10)から化合物(11)を製造する工程である。
(工程2−4)
本工程は、工程1−2と同様にして、化合物(5)及び化合物(11)から化合物(12)を製造する工程である。
(工程2−5)
本工程は、工程1−3と同様にして、化合物(12)から化合物(13)を製造する工程である。
(工程2−6)
本工程は、反応に不活性な溶媒中、ルイス酸の存在下、化合物(13)から本発明の化合物(1b)を製造する工程である。
(製造法3)
製造法3は、本発明の化合物(1)におけるAが水素原子であり、Lが式−OCH2−で表される基であり、かつ、Xが式=CH−で表される基である化合物(1c)を製造する方法である。
(工程3−1)
本工程は、反応に不活性な溶媒中、塩基の存在下、化合物(14)及び化合物(15)から化合物(16)を製造する工程である。
(工程3−2)
本工程は、反応に不活性な溶媒中、パラジウム触媒及び配位子の存在下、化合物(16)及び化合物(17)から化合物(18)を製造する工程である。
(工程3−3)
本工程は、反応に不活性な溶媒中、縮合剤及び塩基の存在下、化合物(18)及び化合物(19)から化合物(20)を製造する工程である。
(工程3−4)
本工程は、工程2−2と同様にして、化合物(20)から本発明の化合物(1c)を製造する工程である。
上記の各工程により得られた反応生成物は、無溶媒和物、その塩又は水和物等の各種の溶媒和物として単離され精製される。塩は通常の方法により製造できる。単離又は精製は、抽出、濃縮、留去、結晶化、ろ過、再結晶、各種クロマトグラフィー等の、通常の方法を適用して行われる。
(実施例1)
4−({5−[(2,4−ジクロロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
1H-NMR (400MHz, DMSO-D6) δ: 9.31 (1H, brs), 8.39 (1H, s), 7.62 (1H, d, J = 2 Hz), 7.41 (1H, dd, J= 8 Hz, 2 Hz), 7.33 (1H, d, J = 8 Hz), 4.50 (2H, d, J = 6 Hz).
(2)4−({5−[(2,4−ジクロロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸tert−ブチル
MS m/z: 469 (M+H)+.
(3)4−({5−[(2,4−ジクロロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
4−({5−[(2,4−ジクロロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸tert−ブチル(425 mg)のトリフルオロ酢酸溶液(3 mL)を、室温で30分間静置した。反応液にエーテル(60 mL)を加え、生じた懸濁液をろ過した。ろ取物をエーテルで洗浄し、減圧下で乾燥後、逆相高速液体クロマトグラフィー(アセトニトリル/水:0.1%ギ酸含む)で精製することにより、標記化合物(144 mg)を得た。
MS m/z: 413 (M+H)+;
1H-NMR (400MHz, DMSO-D6) δ: 8.49 (1H, brs), 7.63 (1H, d, J= 2 Hz), 7.42 (1H, dd, J = 8 Hz, 2 Hz), 7.36 (1H, d, J = 8 Hz), 4.54 (2H, d, J = 6 Hz), 2.73-2.70 (2H, m), 2.56-2.53 (2H, m).
(実施例2)
4−({5−[(2,4−ジフルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
MS m/z: 381 (M+H)+;
1H-NMR (400MHz, DMSO-D6) δ: 9.22-8.38 (1H, brm), 7.40 (1H, td, J= 9 Hz, 7 Hz), 7.24 (1H, ddd, J= 11 Hz, 9 Hz, 3 Hz), 7.06 (1H, tdd, J= 9 Hz, 3 Hz, 1 Hz), 4.50 (2H, d, J= 6 Hz), 2.73-2.69 (2H, m), 2.56-2.53 (2H, m).
(実施例3)
4−({5−[(2−クロロ−4−フルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
MS m/z: 397 (M+H)+;
1H-NMR (400MHz, DMSO-D6) δ: 8.61-8.33 (1H, brm), 7.46 (1H, dd, J= 9 Hz, 3 Hz), 7.41 (1H, dd, J= 9 Hz, 6 Hz), 7.21 (1H, td, J= 9 Hz, 3 Hz), 4.53 (2H, d, J = 6 Hz), 2.77-2.65 (2H, m), 2.56-2.53 (2H, m).
(実施例4)
4−{[4−ヒドロキシ−5−(p−トリルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸
MS m/z: 359 (M+H)+;
1H-NMR (400MHz, DMSO-d6) δ: 8.36 (1H, brs), 7.19 (2H, d, J = 8 Hz), 7.14 (2H, d, J = 8 Hz), 4.45 (2H, d, J = 6 Hz), 2.73-2.67 (2H, m), 2.56-2.51 (2H, m), 2.28 (3H, s).
(実施例5)
4−({5−[(4−フルオロ−3−フェニルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
1H-NMR (400MHz, CDCl3) δ: 7.57-7.54 (2H, m), 7.47-7.42 (2H, m), 7.40-7.37 (2H, m), 7.26-7.25 (1H, m), 7.12 (1H, dd, J = 10 Hz, 8 Hz), 3.90 (2H, s).
(2)4−({5−[(4−フルオロ−3−フェニルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
実施例1の方法に準じ、(2,4−ジクロロフェニル)メタンアミンの代わりに(4−フルオロ−3−フェニルフェニル)メタンアミンを用い、標記化合物を得た。
MS m/z: 439 (M+H)+;
1H-NMR (400MHz, DMSO-D6) δ: 9.29-8.61 (1H, brm), 7.54-7.50 (5H, m), 7.45-7.41 (1H, m), 7.39-7.35 (1H, m), 7.29 (1H, dd, J = 11 Hz, 8 Hz), 4.55 (2H, d, J = 6 Hz), 2.74-2.71 (2H, m), 2.58-2.55 (2H, m).
(実施例6)
4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]ピリミジン−2−イル}アミノ)−4−オキソブタン酸
1H-NMR (400MHz, CDCl3) δ: 9.32 (1H, brs), 8.85 (1H, brs), 7.59-7.31 (10H, m), 4.69 (2H, d, J = 6 Hz), 2.72-2.63 (4H, m), 1.45 (9H, s).
(2)4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]ピリミジン−2−イル}アミノ)−4−オキソブタン酸
4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]ピリミジン−2−イル}アミノ)−4−オキソブタン酸tert−ブチル(110 mg)のトリフルオロ酢酸溶液(1.5 mL)を、室温で1時間静置した。反応液にエーテル(30 mL)を加え、生じた懸濁液をろ過した。ろ取物をエーテル及びヘキサンで洗浄し、減圧下で乾燥することにより、標記化合物(88 mg)を得た。
MS m/z: 421 (M+H)+;
1H-NMR (400MHz, DMSO-D6) δ: 8.53 (1H, brs), 7.65-7.30 (9H, m), 4.57 (2H, d, J = 6 Hz), 2.72-2.69 (2H, m), 2.56-2.53 (2H, m).
(実施例7)
4−[(5−{[4−(2−シアノフェニル)フェニル]メチルカルバモイル}−4−ヒドロキシピリミジン−2−イル)アミノ]−4−オキソブタン酸
MS m/z: 446 (M+H)+;
1H-NMR (400MHz, DMSO-D6) δ: 8.64 (1H, brs), 7.95 (1H, dd, J = 8 Hz, 1 Hz), 7.79 (1H, td, J = 8 Hz, 1 Hz), 7.63-7.54 (4H, m), 7.46 (2H, d, J = 8 Hz), 4.59 (2H, d, J = 6 Hz), 2.74-2.70 (2H, m), 2.56-2.53 (2H, m).
(実施例8)
4−[(5−{[3−(2−シアノフェニル)フェニル]メチルカルバモイル}−4−ヒドロキシピリミジン−2−イル)アミノ]−4−オキソブタン酸
1H-NMR (400MHz, DMSO-D6) δ: 8.41 (3H, brs), 7.99 (1H, d, J = 8 Hz), 7.86-7.82 (1H, m), 7.71 (1H, s), 7.65-7.59 (5H, m), 4.13 (2H, s).
(2)4−[(5−{[3−(2−シアノフェニル)フェニル]メチルカルバモイル}−4−ヒドロキシピリミジン−2−イル)アミノ]−4−オキソブタン酸
実施例6の方法に準じ、(3−フェニルフェニル)メタンアミンの代わりに2−[3−(アミノメチル)フェニル]ベンゾニトリル 塩酸塩を用い、標記化合物を得た。
MS m/z: 446 (M+H)+;
1H-NMR (400MHz, DMSO-D6) δ: 8.62 (1H, brs), 7.95 (1H, dd, J = 8 Hz, 1 Hz), 7.80 (1H, td, J = 8 Hz, 1 Hz), 7.62-7.57 (2H, m), 7.53-7.43 (4H, m), 4.59 (2H, d, J = 6 Hz), 2.73-2.69 (2H, m), 2.56-2.53 (2H, m).
(実施例9)
4−[(4−ヒドロキシ−5−{[(6−メトキシピリジン−3−イル)(テトラヒドロ−2H−ピラン−4−イル)メチル]カルバモイル}ピリミジン−2−イル)アミノ]−4−オキソブタン酸 トリフルオロ酢酸塩
MS m/z: 460 (M+H)+;
1H-NMR (500MHz, DMSO-d6) δ: 8.53-8.29 (1H, m), 8.09 (1H, d, J = 2 Hz), 7.65 (1H, dd, J = 9 Hz, 2 Hz), 6.81 (1H, d, J = 9 Hz), 4.79 (1H, t, J = 8 Hz), 3.90-3.77 (2H, m), 3.82 (3H, s), 3.29-3.17 (2H, m), 2.73-2.68 (2H, m), 2.57-2.52 (2H, m), 2.05-1.94 (1H, m), 1.67-1.59 (1H, m), 1.30-1.17 (3H, m).
(実施例10)
4−{[4−ヒドロキシ−5−({1−[6−(4−メトキシフェニル)ピリジン−3−イル]−1−メチルエチル}カルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸 トリフルオロ酢酸塩
MS m/z: 480 (M+H)+;
1H-NMR (500MHz, DMSO-d6) δ: 9.38 (1H, brs), 8.62 (1H, s), 8.50 (1H, brs), 8.25 (1H, brs), 8.01 (2H, d, J = 9 Hz), 7.90-7.83 (2H, m), 7.06 (2H, d, J = 9 Hz), 3.82 (3H, s), 2.77-2.65 (2H, m), 2.58-2.53 (2H, m), 1.72 (6H, s).
(実施例11)
4−[(4−ヒドロキシ−5−{[3−(トリフルオロメチル)フェニル]メチルカルバモイル}ピリミジン−2−イル)アミノ]−4−オキソブタン酸
MS m/z: 413 (M+H)+;
1H-NMR (500MHz, DMSO-d6) δ: 8.35 (1H, brs), 7.66 (1H, s), 7.63-7.56 (3H, m), 4.59 (2H, d, J = 6 Hz), 2.75-2.67 (2H, m), 2.56-2.54 (2H, m).
(実施例12)
4−({5−[(3−フルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
MS m/z: 363 (M+H)+;
1H-NMR (500MHz, DMSO-d6) δ: 8.35 (1H, brs), 7.38 (1H, dd, J = 14 Hz, 7 Hz), 7.16-7.06 (3H, m), 4.52 (2H, d, J = 6 Hz), 2.73-2.69 (2H, m), 2.56-2.51 (2H, m).
(実施例13)
4−({5−[(3,4−ジフルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
MS m/z: 381 (M+H)+;
1H-NMR (500MHz, DMSO-d6) δ: 8.34 (1H, brs), 7.41-7.34 (2H, m), 7.17-7.15 (1H, m), 4.48 (2H, d, J = 5 Hz), 2.73-2.69 (2H, m), 2.56-2.54 (2H, m).
(実施例14)
4−{[4−ヒドロキシ−5−(m−トリルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸
MS m/z: 359 (M+H)+;
1H-NMR (400MHz, DMSO-d6) δ: 8.35 (1H, s), 7.22 (1H, t, J = 7 Hz), 7.11-7.06 (3H, m), 4.46 (2H, d, J = 5 Hz), 2.72-2.67 (2H, m), 2.56-2.53 (2H, m), 2.29 (3H, s).
(実施例15)
4−{[4−ヒドロキシ−5−(1−ナフチルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸
MS m/z: 395 (M+H)+;
1H-NMR (400MHz, DMSO-d6) δ: 8.39 (1H, brs), 8.12 (1H, t, J = 7 Hz), 7.97 (1H, dd, J = 7 Hz, 2 Hz), 7.88 (1H, d, J = 7 Hz), 7.60-7.53 (2H, m), 7.51-7.46 (2H, m), 4.97 (2H, t, J = 6 Hz), 2.74-2.65 (2H, m), 2.55-2.51 (2H, m).
(実施例16)
4−{[4−ヒドロキシ−5−(2−ナフチルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸
MS m/z: 395 (M+H)+;
1H-NMR (500MHz, DMSO-d6) δ: 8.40 (1H, brs), 7.90-7.87 (3H, m), 7.80 (1H, s), 7.52-7.47 (3H, m), 4.67 (2H, d, J = 6 Hz), 2.74-2.70 (2H, m), 2.56-2.51 (2H, m).
(実施例17)
4−({5−[(3−シクロペンチルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
1H-NMR (400MHz, CDCl3) δ: 7.35 (1H, s), 7.34 (1H, d, J = 2 Hz), 7.25 (1H, dd, J = 8 Hz, 2 Hz), 7.14 (1H, d, H = 8 Hz), 6.19-6.13 (1H, m), 4.77 (2H, s), 2.73-2.65 (2H, m), 2.56-2.48 (2H, m), 2.05-1.96 (2H, m), 1.46 (18H, s).
(2)N−tert−ブトキシカルボニル−N−[(3−シクロペンチルフェニル)メチル]カルバミン酸tert−ブチル
1H-NMR (400MHz, CDCl3) δ: 7.25-7.06 (4H, m), 4.76 (2H, s), 3.02-2.89 (1H, m), 2.10-1.99 (2H, m), 1.84-1.73 (2H, m), 1.73-1.62 (2H, m), 1.61-1.50 (2H, m), 1.45 (18H, s).
(3)(3−シクロペンチルフェニル)メタンアミン 塩酸塩
MS m/z: 176 (M+H)+;
1H-NMR (400MHz, DMSO-D6) δ: 8.29 (3H, brs), 7.39 (1H, s), 7.37-7.21 (3H, m), 3.99 (2H, s), 3.02-2.90 (1H, m), 2.07-1.95 (2H, m), 1.86-1.73 (2H, m), 1.72-1.60 (2H, m), 1.60-1.49 (2H, m).
(4)4−({5−[(3−シクロペンチルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸
実施例6の方法に準じ、(3−フェニルフェニル)メタンアミンの代わりに(3−シクロペンチルフェニル)メタンアミン 塩酸塩を用い、標記化合物を得た。
MS m/z: 413 (M+H)+;
1H-NMR (500MHz, DMSO-d6) δ: 8.35 (1H, brs), 7.24 (1H, t, J = 8 Hz), 7.19 (1H, s), 7.14 (1H, d, J = 7 Hz), 7.10 (1H, d, J = 7 Hz), 4.47 (2H, d, J = 5 Hz), 2.97-2.91 (1H, m), 2.72-2.68 (2H, m), 2.56-2.53 (2H, m), 2.02-1.97 (2H, m), 1.79-1.72 (2H, m), 1.67-1.59 (2H, m), 1.54-1.47 (2H, m).
(実施例18)
4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]−2−ピリジル}アミノ)−4−オキソブタン酸
1H-NMR (400MHz, CDCl3) δ: 8.58 (1H, s), 7.19 (1H, d, J = 8 Hz), 6.47 (1H, d, J = 2 Hz), 6.44 (1H, dd, J = 8 Hz, 2 Hz), 5.83 (1H, s), 5.35 (1H, t, J = 6 Hz), 4.43 (2H, d, J = 6 Hz), 3.86 (3H, s), 3.84 (3H, s), 3.82 (3H, s), 3.80 (3H, s).
(2)6−[(2,4−ジメトキシフェニル)メチルアミノ]−4−メトキシピリジン−3−カルボン酸
1H-NMR (400MHz, CDCl3) δ: 8.68 (1H, s), 7.20 (1H, d, J = 8 Hz), 6.47 (1H, d, J = 2 Hz), 6.44 (1H, dd, J = 8 Hz, 2 Hz), 5.86 (1H, s), 4.45 (2H, d, J = 6 Hz), 3.93 (3H, s), 3.84 (3H, s), 3.80 (3H, s).
(3)4−[(2,4−ジメトキシフェニル)メチル−{4−メトキシ−5−[(3−フェニルフェニル)メチルカルバモイル]−2−ピリジル}アミノ]−4−オキソブタン酸tert−ブチル
MS m/z: 640 (M+H)+.
(4)4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]−2−ピリジル}アミノ)−4−オキソブタン酸
4−[(2,4−ジメトキシフェニル)メチル−{4−メトキシ−5−[(3−フェニルフェニル)メチルカルバモイル]−2−ピリジル}アミノ]−4−オキソブタン酸tert−ブチルを含む混合物(345 mg)のトリフルオロ酢酸溶液(4 mL)を、室温で17時間静置した。反応液にエーテル(60 mL)を加えた。生じた懸濁液をろ過し、ろ取物をエーテルで洗浄し、減圧下で乾燥させた。得られた残渣に三臭化ホウ素/ジクロロメタン溶液(1 M, 6 mL)を室温で加え、40℃で6時間撹拌した。反応混合物を室温まで冷却後、水を加えた。生じた懸濁液をろ過し、ろ取物を水及びエーテルで洗浄した。得られた残渣をエタノールに懸濁させ、超音波浴槽で15分間振とう後、ろ過した。ろ取物を減圧下で乾燥させることにより、標記化合物(56.7 mg)を得た。
MS m/z: 420 (M+H)+;
1H-NMR (400MHz, DMSO-D6) δ: 8.34 (1H, d, J= 6 Hz), 7.64-7.54 (4H, m), 7.49-7.29 (5H, m), 5.95 (1H, s), 4.57 (2H, d, J = 6 Hz), 2.66-2.62 (2H, m), 2.56-2.52 (2H, m).
(実施例19)
4−オキソ−4−({5−[(4−フェニルフェニル)メトキシメチル]−2−ピリジル}アミノ)ブタン酸
1H-NMR (400MHz, CDCl3) δ: 8.38 (1H, s), 7.69 (1H, d, J = 4 Hz), 7.65-7.54 (4H, m), 7.52-7.30 (5H, m), 7.29-7.22 (1H, m), 4.62 (2H, s), 4.57 (2H, s).
(2)5−[(4−フェニルフェニル)メトキシメチル]ピリジン−2−アミン
1H-NMR (400MHz, CDCl3) δ: 8.06 (1H, d, J = 4 Hz), 7.63-7.57 (4H, m), 7.50 (1H, dd, J = 8 Hz, 4 Hz), 7.47-7.40 (4H, m), 7.35 (1H, t, J = 8 Hz), 6.52 (1H, d, J = 8 Hz), 4.56 (2H, s), 4.44 (2H, s), 4.40 (2H, brs).
(3)4−オキソ−4−({5−[(4−フェニルフェニル)メトキシメチル]−2−ピリジル}アミノ)ブタン酸メチル
1H-NMR (400MHz, CDCl3) δ: 8.27 (1H, d, J = 4 Hz), 8.18 (1H, d, J = 8 Hz), 8.09 (1H, brs), 7.72 (1H, dd, J = 8 Hz, 4 Hz), 7.64-7.57 (4H, m), 7.48-7.41 (4H, m), 7.36 (1H, t, J = 8 Hz), 4.60 (2H, s), 4.54 (2H, s), 3.72 (3H, s), 2.80-2.69 (4H, m).
(4)4−オキソ−4−({5−[(4−フェニルフェニル)メトキシメチル]−2−ピリジル}アミノ)ブタン酸
4−オキソ−4−({5−[(4−フェニルフェニル)メトキシメチル]−2−ピリジル}アミノ)ブタン酸メチル(0.168 g)をテトラヒドロフラン(3 mL)及びメタノール(1 mL)の混合溶媒に溶解し、室温で水酸化ナトリウム水溶液(1 M, 0.830 mL)を加え、1時間撹拌した。反応液に塩酸(1 M, 0.830 mL)を添加し、0℃で撹拌した。生じた懸濁液をろ過し、ろ取物を水洗し、減圧下で乾燥させることにより、標記化合物(0.150 g)を得た。
MS m/z: 389 (M-H)+;
1H-NMR (400MHz, DMSO-d6) δ: 12.13 (1H, s), 10.56 (1H, s), 8.30 (1H, d, J= 4 Hz), 8.07 (1H, d, J = 8 Hz), 7.77 (1H, dd, J = 8 Hz, 4 Hz), 7.70-7.65 (4H, m), 7.51-7.43 (4H, m), 7.36 (1H, t, J = 8 Hz), 4.57 (2H, s), 4.53 (2H, s), 2.66-2.60 (2H, m), 2.53-2.47 (2H, m).
(実施例20)
4−[(5−{[4−(2−シアノフェニル)フェニル]メトキシメチル}−2−ピリジル)アミノ]−4−オキソブタン酸
MS m/z: 414 (M-H)+;
1H-NMR (400MHz, DMSO-d6) δ: 12.14 (1H, s), 10.57 (1H, s), 8.32 (1H, d, J = 4 Hz), 8.08 (1H, d, J = 8 Hz), 7.96 (1H, dd, J = 8 Hz, 4 Hz), 7.85-7.78 (2H, m), 7.63-7.50 (6H, m), 4.62 (2H, s), 4.56 (2H, s), 2.69-2.60 (2H, m), 2.54-2.48 (2H, m).
(製剤例)
製剤例1(注射剤)
1.5重量%の実施例化合物を、10容量%のプロピレングリコール中で攪拌し、次いで、注射用水で一定容量に調整した後、滅菌して注射剤とする。
製剤例2(ハードカプセル剤)
100 mgの粉末状の実施例化合物、128.7 mgのラクトース、70 mgのセルロース及び1.3 mgのステアリン酸マグネシウムを混合し、60メッシュのふるいを通した後、得られた粉末を250 mgの3号ゼラチンカプセルに入れ、カプセル剤とする。
製剤例3(錠剤)
100 mgの粉末状の実施例化合物、124 mgのラクトース、25 mgのセルロース及び1 mgのステアリン酸マグネシウムを混合し、打錠機により打錠して、1錠250 mgの錠剤とする。この錠剤は必要に応じて糖衣を施すことができる。
(試験例)
本発明の化合物の薬理活性は、以下の試験により確認した。
(表1)
______________________
実施例化合物番号 EPO濃度(倍)
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
Control (0.5% DMSO) 1
1 3.6
2 7.9
3 9.5
5 6.3
6 3.7
9 16
10 10
11 7.5
12 7.2
13 13
14 3.0
17 4.4
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
Claims (19)
- 一般式(1)
R1は、独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよい芳香族炭化水素環基、又は独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよい芳香族複素環基を示し、
置換基群αは、ハロゲン原子、C1〜C4アルキル基、ハロゲノC1〜C4アルキル基、C1〜C4アルコキシ基、C3〜C6シクロアルキル基、又はR4が置換していてもよい芳香族炭化水素環基からなる群を示し、
R2は、水素原子、C1〜C4アルキル基、又は4〜7員ヘテロシクロアルキル基を示し、
R3は、水素原子、又はC1〜C4アルキル基を示し、
R4は、シアノ基、ハロゲン原子、又はC1〜C4アルコキシ基を示し、
Aは、水素原子、又は水酸基を示し、
Lは、式−NHCO−で表される基、又は式−OCH2−で表される基を示し、
Xは、窒素原子、又は式=CH−で表わされる基を示す。]
で表される化合物、又はその薬理上許容される塩。 - R1が、独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよいフェニル基、ナフチル基、ピリジル基、ピリミジニル基、ピラジニル基、又はピリダジニル基である請求項1に記載の化合物、又はその薬理上許容される塩。
- R1が、独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよいフェニル基、ナフチル基、又はピリジル基である請求項1に記載の化合物、又はその薬理上許容される塩。
- R1が、独立して置換基群αから選ばれる置換基を1個若しくは2個有していてもよいフェニル基、又はピリジル基である請求項1に記載の化合物、又はその薬理上許容される塩。
- 置換基群αが、フッ素原子、塩素原子、メチル基、トリフルオロメチル基、メトキシ基、シクロペンチル基、又はR4が置換していてもよいフェニル基からなる群であり、
R4が、シアノ基、又はメトキシ基である請求項1乃至4のいずれか1項に記載の化合物、又はその薬理上許容される塩。 - 置換基群αが、フッ素原子、塩素原子、トリフルオロメチル基、メトキシ基、又はR4が置換していてもよいフェニル基からなる群であり、
R4がメトキシ基である請求項1乃至4のいずれか1項に記載の化合物、又はその薬理上許容される塩。 - R2が、水素原子、メチル基、又はテトラヒドロピラニル基である請求項1乃至6のいずれか1項に記載の化合物、又はその薬理上許容される塩。
- R3が、水素原子、又はメチル基である請求項1乃至7のいずれか1項に記載の化合物、又はその薬理上許容される塩。
- Aが、水酸基である請求項1乃至8のいずれか1項に記載の化合物、又はその薬理上許容される塩。
- Lが、式−NHCO−で表される基である請求項1乃至9のいずれか1項に記載の化合物、又はその薬理上許容される塩。
- Xが、窒素原子である請求項1乃至10いずれか1項に記載の化合物、又はその薬理上許容される塩。
- 請求項1において、下記から選ばれる化合物、又はその薬理上許容される塩:
4−({5−[(2,4−ジクロロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({5−[(2,4−ジフルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({5−[(2−クロロ−4−フルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(p−トリルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−({5−[(4−フルオロ−3−フェニルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]ピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−[(5−{[4−(2−シアノフェニル)フェニル]メチルカルバモイル}−4−ヒドロキシピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−[(5−{[3−(2−シアノフェニル)フェニル]メチルカルバモイル}−4−ヒドロキシピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−[(4−ヒドロキシ−5−{[(6−メトキシピリジン−3−イル)(テトラヒドロ−2H−ピラン−4−イル)メチル]カルバモイル}ピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−({1−[6−(4−メトキシフェニル)ピリジン−3−イル]−1−メチルエチル}カルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−[(4−ヒドロキシ−5−{[3−(トリフルオロメチル)フェニル]メチルカルバモイル}ピリミジン−2−イル)アミノ]−4−オキソブタン酸、
4−({5−[(3−フルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({5−[(3,4−ジフルオロフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(m−トリルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(1−ナフチルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−{[4−ヒドロキシ−5−(2−ナフチルメチルカルバモイル)ピリミジン−2−イル]アミノ}−4−オキソブタン酸、
4−({5−[(3−シクロペンチルフェニル)メチルカルバモイル]−4−ヒドロキシピリミジン−2−イル}アミノ)−4−オキソブタン酸、
4−({4−ヒドロキシ−5−[(3−フェニルフェニル)メチルカルバモイル]−2−ピリジル}アミノ)−4−オキソブタン酸、
4−オキソ−4−({5−[(4−フェニルフェニル)メトキシメチル]−2−ピリジル}アミノ)ブタン酸、
4−[(5−{[4−(2−シアノフェニル)フェニル]メトキシメチル}−2−ピリジル)アミノ]−4−オキソブタン酸。 - 請求項1乃至12のいずれか1項に記載の化合物、又はその薬理上許容される塩を有効成分として含有する医薬組成物。
- 貧血の予防及び/又は治療のための、請求項13に記載の医薬組成物。
- エリスロポエチンを産生するための、請求項13に記載の医薬組成物。
- 医薬を製造するための、請求項1乃至12のいずれか1項に記載の化合物、又はその薬理上許容される塩の使用。
- 医薬が、貧血の予防及び/又は治療のための医薬である、請求項16に記載の使用。
- 疾患の治療又は予防のための方法における使用のための、請求項1乃至12のいずれか1項に記載の化合物、又はその薬理上許容される塩。
- 疾患が、貧血である、請求項18に記載の化合物、又はその薬理上許容される塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012079859 | 2012-03-30 | ||
JP2012079859 | 2012-03-30 | ||
PCT/JP2013/059657 WO2013147216A1 (ja) | 2012-03-30 | 2013-03-29 | (2-ヘテロアリールアミノ)コハク酸誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2013147216A1 JPWO2013147216A1 (ja) | 2015-12-14 |
JP6100755B2 true JP6100755B2 (ja) | 2017-03-22 |
Family
ID=49260457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014508120A Expired - Fee Related JP6100755B2 (ja) | 2012-03-30 | 2013-03-29 | (2−ヘテロアリールアミノ)コハク酸誘導体 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9206168B2 (ja) |
EP (1) | EP2832726B1 (ja) |
JP (1) | JP6100755B2 (ja) |
KR (1) | KR20140147825A (ja) |
CN (1) | CN104334528A (ja) |
CA (1) | CA2869135A1 (ja) |
ES (1) | ES2649905T3 (ja) |
HK (1) | HK1204622A1 (ja) |
IN (1) | IN2014DN08653A (ja) |
TW (1) | TW201400458A (ja) |
WO (1) | WO2013147216A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9634549B2 (en) | 2013-10-31 | 2017-04-25 | General Electric Company | Dual phase magnetic material component and method of forming |
TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
EP3994125A1 (en) * | 2019-07-02 | 2022-05-11 | Regeneron Pharmaceuticals, Inc. | Modulators of hsd17b13 and methods of use thereof |
CN111559982B (zh) * | 2020-06-09 | 2023-04-07 | 天津市医药科学研究所 | 2-(2-取代-4-羟基嘧啶-5-甲酰胺基)乙酸类化合物及其制备方法与用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239109B1 (en) * | 1998-02-09 | 2001-05-29 | University Of Southern California | Method of promoting erythropoiesis |
US7799827B2 (en) * | 2002-03-08 | 2010-09-21 | Eisai Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
EP1893186A2 (en) * | 2005-06-06 | 2008-03-05 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
EP4095127A1 (en) * | 2006-06-26 | 2022-11-30 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
CN102036981B (zh) | 2008-03-18 | 2015-04-08 | 默沙东公司 | 取代的4-羟基嘧啶-5-甲酰胺 |
AP2014007897A0 (en) * | 2008-04-01 | 2014-08-31 | Weir Minerals Australia Ltd | A lifter bar assembly for a crushing mill and method of installation |
KR20110006662A (ko) * | 2008-04-22 | 2011-01-20 | 다이이찌 산쿄 가부시키가이샤 | 5-하이드록시피리미딘-4-카르복사미드 화합물 |
AU2010266559A1 (en) | 2009-06-30 | 2011-12-15 | Merck Sharp & Dohme Corp. | Substituted 4-hydroxypyrimidine-5-carboxamides |
EP2448583B1 (en) | 2009-06-30 | 2014-06-25 | Merck Sharp & Dohme Corp. | Substituted 4-hydroxypyrimidine-5-carboxamides |
DK2492266T3 (en) * | 2009-10-21 | 2015-12-07 | Daiichi Sankyo Co Ltd | 5-hydroxypyrimidine-4-carboxamide |
JP2011105708A (ja) * | 2009-10-21 | 2011-06-02 | Daiichi Sankyo Co Ltd | 5−ヒドロキシピリミジン−4−カルボキサミド化合物を含有する医薬組成物 |
JP2011088840A (ja) * | 2009-10-21 | 2011-05-06 | Daiichi Sankyo Co Ltd | 5−ヒドロキシピリミジン−4−カルボキサミド化合物を含有する医薬組成物 |
TWI412114B (zh) * | 2009-12-31 | 2013-10-11 | Advanced Semiconductor Eng | 半導體封裝結構及其製造方法 |
WO2011132633A1 (ja) | 2010-04-19 | 2011-10-27 | 第一三共株式会社 | 置換5-ヒドロキシピリミジン-4-カルボキサミド化合物 |
-
2013
- 2013-03-29 CN CN201380027575.6A patent/CN104334528A/zh active Pending
- 2013-03-29 EP EP13769439.4A patent/EP2832726B1/en not_active Not-in-force
- 2013-03-29 JP JP2014508120A patent/JP6100755B2/ja not_active Expired - Fee Related
- 2013-03-29 CA CA2869135A patent/CA2869135A1/en not_active Abandoned
- 2013-03-29 ES ES13769439.4T patent/ES2649905T3/es active Active
- 2013-03-29 IN IN8653DEN2014 patent/IN2014DN08653A/en unknown
- 2013-03-29 KR KR1020147026676A patent/KR20140147825A/ko not_active Application Discontinuation
- 2013-03-29 WO PCT/JP2013/059657 patent/WO2013147216A1/ja active Application Filing
- 2013-03-29 TW TW102111316A patent/TW201400458A/zh unknown
-
2014
- 2014-09-24 US US14/495,337 patent/US9206168B2/en not_active Expired - Fee Related
-
2015
- 2015-06-03 HK HK15105297.2A patent/HK1204622A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2869135A1 (en) | 2013-10-03 |
CN104334528A (zh) | 2015-02-04 |
EP2832726B1 (en) | 2017-09-06 |
EP2832726A4 (en) | 2015-12-02 |
WO2013147216A1 (ja) | 2013-10-03 |
IN2014DN08653A (ja) | 2015-05-22 |
ES2649905T3 (es) | 2018-01-16 |
KR20140147825A (ko) | 2014-12-30 |
JPWO2013147216A1 (ja) | 2015-12-14 |
US20150011574A1 (en) | 2015-01-08 |
US9206168B2 (en) | 2015-12-08 |
TW201400458A (zh) | 2014-01-01 |
HK1204622A1 (en) | 2015-11-27 |
EP2832726A1 (en) | 2015-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021078285A1 (zh) | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 | |
TWI551595B (zh) | 2,4-disubstituted benzene-1,5-diamine derivatives and their use, Its preparation of pharmaceutical compositions and pharmaceutical compositions | |
CA2903288C (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
JP2020525513A (ja) | 癌および他の疾患を治療するためのatf4阻害剤としてのn−(3−(2−(4−クロロフェノキシ)アセトアミドビシクロ[1.1.1]ペンタン−1−イル)−2−シクロブタン−1−カルボキサミド誘導体および関連化合物 | |
CN109790166A (zh) | 咪唑并吡啶化合物用于治疗癌症 | |
JP2021529814A (ja) | 化学化合物 | |
EA007063B1 (ru) | ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β; | |
JP7352294B2 (ja) | ムスカリン性アセチルコリン受容体m4のアンタゴニスト | |
JP6100755B2 (ja) | (2−ヘテロアリールアミノ)コハク酸誘導体 | |
WO2020031107A1 (en) | Chemical compounds | |
JPWO2016031987A1 (ja) | オートタキシン阻害活性を有するピリミジノン誘導体 | |
CA2831356A1 (en) | Imidazo [1,2-a]pyridine_compounds for use in therapy | |
JP7016471B2 (ja) | ムスカリン性アセチルコリンレセプターm4のポジティブアロステリック調節因子 | |
JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
JP2020527166A (ja) | Bcl−2タンパク質を阻害するためのN−ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 | |
JP2020522553A (ja) | Atf4経路阻害剤としての化合物 | |
JP2024050645A (ja) | ヘテロアリールで置換されたピラゾール化合物及びその医薬用途 | |
WO2021052501A1 (zh) | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 | |
WO2020010003A1 (en) | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS | |
JP2018511627A (ja) | Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用 | |
JPWO2017018495A1 (ja) | シクロプロパン誘導体及びそれを含有する医薬 | |
CN117355507A (zh) | 用作lrrk2激酶抑制剂的嘧啶衍生物 | |
JP6126078B2 (ja) | 4−アルカノイルアミノ−3−ピラゾロン誘導体 | |
CA3100095C (en) | Indoline-1-carboxamide compound, preparation method therefor and medical use thereof | |
CN103319456B (zh) | 二氢吡啶类化合物、其组合物、制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170221 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170223 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6100755 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |